Cancer: Molecular & Cellular Analysis Technology

Deadline
Multiple
OPPORTUNITY NO.
RFA-CA-17-010
MECHANISM
R21 (also available: R33)
RESEARCH AREA(S)
SYNOPSIS

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Deadlines:

  • Pre-Application Submission: 30 days before application submission due date
  • Application Submission: 5:00 PM local time of applicant organization, Feb. 28, 2017; May 26, 2017; Sep. 26, 2017

Companion Opportunity:

ELIGIBILITY

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.